During the third quarter, Bank Pictet & Cie Europe AG increased its holding in Gilead Sciences by 502.8%, acquiring an additional 12,752 shares to reach a total of 15,288 shares valued at approximately 1.697 million. Other major institutional moves in the second quarter included Invesco Ltd. adding 3.39 million shares for a 33.5% rise in its stake to 13.52 million shares, Sivik Global Healthcare LLC boosting its position by 25% to 50,000 shares, One Wealth Advisors LLC increasing its stake by 34.8% to 9,163 shares, and Lombard Odier Asset Management Switzerland SA expanding its holdings by 24.6% to 53,312 shares. Jump Financial LLC also initiated a new position worth roughly 6.99 million. Collectively, institutional investors now account for 83.67% ownership of the company’s stock, underscoring broad confidence in Gilead’s cash-generative profile.

In its latest quarterly release, Gilead reported earnings per share of 2.47, surpassing the consensus estimate of 2.16 by 0.31, while revenue climbed 3.0% year-over-year to 7.77 billion versus analyst projections of 7.42 billion. The company achieved a return on equity of 51.86% and a net margin of 27.88%, reflecting strong operational efficiency. Following the beat, Gilead updated its full-year guidance, forecasting adjusted EPS in the range of 8.050 to 8.250, compared with the prior outlook centered around 7.95. This upward revision signals management’s confidence in sustained cash flow strength and underlying demand across its antiviral and oncology franchises.

Several major research firms have recently lifted their targets and ratings on Gilead Sciences. Rothschild & Co Redburn raised its price objective from 143.00 to 153.00, while Goldman Sachs increased its target from 108.00 to 110.00 and maintained a neutral stance. Citigroup upgraded its target from 125.00 to 135.00 with a buy rating, and Scotiabank initiated coverage with a sector outperform recommendation and a 140.00 target. DBS Bank retains a moderate buy assessment. On balance, two analysts assign a strong buy, twenty-two rate the shares as buy, and four view them as hold, producing an average consensus target of 131.68 and an overall moderate buy consensus, reflecting growing optimism around the company’s cash-flow generation and pipeline prospects.